In 2002, hydrogen sulfide was identified as one of three biologically important gases, now collectively termed “gasotransmitters”. Previously viewed as hostile to life, hydrogen sulfide—along with nitric oxide and carbon monoxide—have come to be recognized as central to a wide range of key cellular functions. In 2003, Dr. Wallace and his colleagues identified hydrogen sulfide’s anti-inflammatory properties. Over the succeeding years, their work would demonstrate hydrogen sulfide’s gastrointestinal-protective potential, leading to the design of Antibe’s drug platform.
